Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes: Study protocol of a randomized controlled trial

Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. This current research is a double blinded, randomized, and prospective trial to determine the effect of dapagliflozin on cardiovascular outcomes...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Medicine (Baltimore) 2020-10, Vol.99 (41), p.e22660-e22660
Hauptverfasser:	Yin, Dong, Hui, Yuan, Yang, Chuanhui, Xu, Yi
Format:	Artikel
Sprache:	eng
Schlagworte:	Benzhydryl Compounds - therapeutic use Cardiovascular Diseases - etiology Cardiovascular Diseases - prevention & control Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Glucosides - therapeutic use Humans Randomized Controlled Trials as Topic Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Study Protocol Clinical Trial
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!